Tenet Healthcare: Options Turn Cautious Before Monday's Print

Tenet Healthcare Corporation, a major US hospital and ambulatory surgery operator, reports third-quarter results on Monday after the close, with shares at $268.45 after a modest 0.4% gain on the week.

The clearest pre-earnings signal is in options. The put/call ratio has climbed to 0.97, more than two standard deviations above its 20-day average of 0.91. That is the most defensive positioning seen in the options market for this stock in recent weeks, suggesting traders are paying noticeably more for downside protection than they have been. The shift is all the more striking because the lending market tells the opposite story: short interest has fallen roughly 7% over the past month to just 2% of the free float, and availability is extraordinarily loose at more than 4,000% of short interest, meaning there are roughly 40 times as many shares available to borrow as are currently borrowed. Borrowing costs remain near zero at 0.24%. The short-selling community is not pressing a thesis here; the caution is coming from the options desk, not from new short positions.

The core debate heading into the print is whether THC's ambulatory surgery segment, USPI, can sustain the margin expansion it delivered through the first half of 2026. The bull case rests on faster growth and superior returns from that business, alongside a better payer mix and easing operational pressure across the hospital network. Guggenheim raised its target to $307 earlier this month while maintaining a Buy, and Leerink Partners holds a $309 target with an Outperform rating. The bear case is more structural: the anticipated expiration of ACA exchange subsidies threatens to strip coverage from 80 to 85% of a vulnerable patient cohort, creating a potential $220 million headwind to the Acute segment and a further $30 million drag on USPI. A one-off $148 million Medicaid state-fund payment boosted a prior quarter's numbers but is unlikely to recur, which complicates year-on-year comparisons. BMO Capital initiated at Market Perform in September with a $265 target, below where the stock trades today, a rare note of caution in an otherwise constructive analyst register.

The insider register adds a layer of context that is hard to ignore. Over the past 90 days, insiders have been consistent net sellers, with the CEO offloading roughly $13.7 million of stock in late August and the COO selling a further $6.4 million. Directors added to those sales in early and mid-September. None of the trades were filed under a pre-arranged 10b5-1 plan, making them discretionary rather than mechanical. The net insider outflow over 90 days amounts to roughly $50 million worth of shares. T. Rowe Price, the largest institutional holder at close to 11% of shares, added more than one million shares as recently as the end of September, providing a counterweight from the buy side.

Monday's release will test whether USPI's growth rate and margin trajectory are sufficient to absorb the looming headwinds from subsidy expiration, and whether the Acute segment can hold revenue without the Medicaid one-off that flattered earlier comparisons.